Home » Topics » BioWorld Science

BioWorld Science
RSS

Gilead Sciences initiates phase Ib/II study of GS-4224 in advanced solid tumors

Sep. 5, 2019

CellCentric initiates phase I/IIa study of CCS-1477 in hematological malignancies

Sep. 5, 2019

Applied Therapeutics begins phase III study of AT-1001 for diabetic cardiomyopathy

Sep. 5, 2019

European Commission approves Stelara for moderate to severely active ulcerative colitis

Sep. 5, 2019

Tonix begins phase I study of TNX-601 for daytime treatment of PTSD

Sep. 5, 2019

First safety data presented from phase II trial of revacept

Sep. 5, 2019

Idera Pharmaceuticals and Abbvie to collaborate on immunooncology trial

Sep. 5, 2019

Optimized liver-directed gene therapy for Pompe's disease evaluated in vivo

Sep. 5, 2019

New CDK7 inhibitors presented by Ancureall Biomedical Technology (Shanghai)

Sep. 5, 2019

Chinese researchers describe BRD4 inhibitors

Sep. 5, 2019

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 2, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for June 30, 2026
CINP 2026: Gut microbiota could predict antidepressant response
BioWorld
The gut microbiota may be altered in people with depression as a result of treatment. These microorganisms reorganize differently in individuals who respond to...
Deep brain stimulation from the shallows: tomorrow’s BCI technology?
BioWorld
Deep brain stimulation (DBS) through implanted electrodes has enabled fundamentally new ways of treating certain disorders. More than 100,000 severely ill...
Ascending BCI systems deepen national security, ethical concerns
BioWorld
Ready or not, the future has arrived. Novel AI and brain-computer interface (BCI) systems are no longer confined to the realm of science fiction. As an...